Objective：This study aims to investigate the expression level of HER2/Ki67 is association with efficacy of anthracycline chemotherapeutic drugs and clinical prognosis in invasive breast cancer. Methods：The expression level of HER2 and Ki67 in invasive breast cancer were predicted by database. The mRNA expression of HER2 in 53 cases of invasive breast cancer FFPE was detected by Nanostring nCounter technique，and the efficacy of anthracycline chemotherapeutic drugs was analyzed. Total 222 cases of invasive breast cancer tissue samples from 2008 to 2012 were collected to analyze the protein expression level of HER2 and Ki67，and the correlation analysis was conducted based on the clinicopathological data and the chemotherapy efficacy of the patients. Results：GEPIA database analysis showed that there was a correlation between the HER2 mRNA and Ki67 mRNA. The expression level of HER2 mRNA in 53 cases of invasive breast cancer was detected by Nanostring nCounter. The positive rate was 16/53（30.19%）and the negative rate was 37/53（69.81%）. Among the HER2 positive patients，chemotherapy was effective in 3 cases（18.80%）and ineffective in 13 cases（81.20%）. In the HER2 negative patients，chemotherapy was effective in 19 cases（51.35%）and ineffective in 18 cases（48.65%）. The results of the clinicopathological data of 222 cases of invasive breast cancer showed that the invasive breast cancer patients with HER2-/KI67+ predicted better chemotherapy efficacy and prognosis. Conclusion：In patients with HER2-negative invasive breast cancer，the high expression of Ki67 indicates a better effect of chemotherapy，while the patients with HER2-/Ki67+ predict a better survival time.